<b>Acquisition of Huxley Pharmaceuticals, Inc. </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On October20, 2009, BioMarin entered into a stock purchase agreement with Huxley Pharmaceuticals, Inc., or Huxley, and the stockholders
of Huxley to acquire all of the outstanding shares of capital stock of Huxley. Huxley had the rights to a proprietary form of 3,4-diaminopyridine, or 3,4-DAP, amifampridine phosphate, which we have branded as Firdapse, for the rare autoimmune
disease Lambert Eaton Myasthenic Syndrome, or LEMS. Under the terms of the stock purchase agreement, on October23, 2009, we purchased all of the capital stock of Huxley for an upfront cash payment to the stockholders of Huxley of $15.0 million
and an additional $1.0 million upon receipt of U.S. Food and Drug Administration, or FDA, orphan drug designation for Firdapse in LEMS, and will pay an additional $6.5 million to the Huxley stockholders for final EMEA approval of Firdapse in LEMS
granted in December 2009. Additionally, Huxley stockholders are eligible to receive up to approximately $36.0 million in milestone payments if certain annual, cumulative sales and U.S. development milestones are met. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Firdapse Marketing Approval in the European Union and Orphan Drug Designation
in the U.S. </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In December 2009, the EMEA
granted marketing approval for 3,4-DAP for LEMS. We will sell our proprietary form of 3,4-DAP under the brand name Firdapse. Firdapse, which was developed by AGEPS, the pharmaceutical unit of the Paris Public Hospital Authority, or AP-HP, and
sublicensed from EUSA Pharma SAS, or EUSA, is the first approved treatment for LEMS, thereby conferring orphan drug protection and providing ten years of market exclusivity in Europe. We expect to begin sales of Firdapse in the European Union, or EU
in March of 2010. We also announced in November 2009 that the FDA
</font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">2 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">
had granted orphan drug designation for Firdapse. We plan to meet with the FDA in the first half of 2010 to determine the regulatory path for Firdapse in the U.S. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Acquisition of LEAD Therapeutics, Inc. </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On February4, 2010, we announced that we entered into a
stock purchase agreement with LEAD Therapeutics, Inc., or LEAD, and the stockholders of LEAD to acquire all of the outstanding shares of capital stock of LEAD. LEAD is a small private drug discovery and early stage development company with a key
compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with some genetically defined cancers. Under the terms of the stock purchase agreement, on February10, 2010, we purchased all of
the capital stock of LEAD for an upfront cash payment to the stockholders of LEAD of $18.0 million and will pay the stockholders an additional $11.0 million upon acceptance of the investigational new drug application, or IND filing expected by the
end of 2010 and up to $68.0 million for development and launch milestones for LT-673, which we now refer to as BMN-673. </font></p><br /><hr noshade=""/><hr noshade=""/><br /><b><i>Business Combinations </i></b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We allocate the purchase price of acquired businesses to the
tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at
acquisition date with respect to intangible assets and in-process research and development. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">39 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Although we believe the assumptions and estimates made are reasonable, they are based in
part on historical experience and information obtained from the management of the acquired businesses and are inherently uncertain. Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the
future include but are not limited to: </font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones; </font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones; </font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones; </font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones; </font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and </font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and </font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and </font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and </font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales; </font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales; </font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales; </font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales; </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with the purchase price allocations for acquisitions, we estimate the fair value of the
contingent payments. The estimated fair value of any contingent payments is determined utilizing a probability-based income approach inclusive of an estimated discount rate. </font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>(5) ACQUISITION OF HUXLEY PHARMACEUTICALS, INC. </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On October23, 2009, the Company acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare
autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS) for a total purchase price of $37.2 million. As a result of the acquisition, the Company will be the first to market an approved treatment for LEMS in Europe. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with its acquisition of Huxley, the Company paid
$15.0 million upfront for all of the outstanding common stock of Huxley. The Company has also agreed to pay Huxley stockholders additional consideration in future periods up to $42.9 million (undiscounted) in milestone payments if certain annual
sales, cumulative sales and development milestones are met. The fair value of the contingent consideration payments was $22.2 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This
estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1)a discount rate of 6.3%; and (2)a probability adjusted contingency. As of December31,
2009, the range of outcomes and assumptions used to develop these estimates have not changed. In November 2009, the FDA granted Firdapse U.S. orphan status, resulting in a payment of $1.0million. In December 2009, the EMEA granted marketing
approval for Firdapse, which will result in a payment of $6.5 million. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-23 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(Continued)
</b></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>December31, 2008 and 2009 </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following table presents the allocation of the purchase consideration, including the
contingent consideration, based on fair value: </font></p>